Onderneming BIND Therapeutics Inc Nasdaq
Aandelen
US05548N1072
Biotechnologie & Medisch Onderzoek
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Zale
CTO | Chief Tech/Sci/R&D Officer | 68 | 01-11-06 |
Tom Baker
IRC | Investor Relations Contact | - | - |
Neil Bander
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | - | 24-07-16 | |
James L. Wright
PRN | Corporate Officer/Principal | 76 | 01-01-07 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Corporate Officer/Principal | - | 24-07-16 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 20 886 802 | 17 860 424 ( 85,51 %) | 0 | 85,51 % |
Bedrijfsgegevens
DNIB Unwind, Inc.
333 South Grand Avenue Suite 4100
90071, Los Angeles
+617-491-3400
http://bindtherapeutics.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
-3,46% | 102 mld. | |
+1,41% | 96,29 mld. | |
+2,13% | 22,18 mld. | |
-15,84% | 21,2 mld. | |
-9,21% | 18,31 mld. | |
-39,98% | 17,38 mld. | |
-14,65% | 16,36 mld. | |
+4,39% | 13,97 mld. | |
+31,35% | 12,17 mld. |